There has been and still is research done on Kratom. On this page I will provide references, links and videos for anyone interested in becoming familiar with the actual science and research that has been and is being conducted and the results of that research. It’s interesting to point out that pretty much all the Kratom researchers and scientists do NOT think Kratom should be classified as a Schedule 1 drug.

Christopher McCurdy Ph.D Video Interview

Christopher McCurdy, Ph.D., is a broadly trained medicinal chemist, behavioral pharmacologist and pharmacist whose research focuses on the design, synthesis and development of drugs to treat pain and drug abuse.He has been researching Kratom for over 15 years and is considered to be one of the worlds foremost authorities and experts on Kratom. In this video interview Dr. Mercola interviews him about Kratom.

It should be interesting to note that he does NOT support the FDA/DEA’s push to to Schedule and ban Kratom.


Kratom Research Presentation Video by Dr. Oliver Grundmann:

Dr. Oliver Grundmann; Clinical Associate Professor, College of Pharmacy at the University of Florida, presents his research on Kratom. This Recording was recorded for graduate students in the online, Pharmaceutical Chemistry, Clinical Toxicology, and Forensic Science programs as part of their educational curriculum.


Pinney Associates Kratom Science Assessment

Kratom-Scientific-Assessment.compressed

Conclusion of Pinney Assessment:We do not recommend scheduling of kratom or any of its specific alkaloids under the Controlled Substances Act.

Kratom has a low potential for abuse and a low dependence liability and there is insufficient evidence of personal harm, adverse health effects or detriment to the public health to warrant control under the CSA.

Effectively banning the availability of kratom through scheduling could precipitate public health problems that do not presently exist or are at very low levels, because this would shift the market place from a largely lawful retail market to illicit manufacturers and distributors with no regulated labeling, purity or content standards, or effective ability to remove adulterated products from the market.

Appropriate regulation of kratom under the FDCA is the most effective way to protect the public health by ensuring appropriate access and oversight and to sustain the overall very low adverse personal and public health effects associated with kratom consumption.

 

Botanical Education and Advocacy Group

A detailed overview of Facts, Scientific Study, and Professional Testimony on Kratom (Mitragyna Speciosa)

Botanical-Alliance-Legal-Fact-Sheet